LRRC20

Across TCGA pan-cancer cohorts, LRRC20 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LRRC20 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LRRC20 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LRRC20 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where LRRC20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.150	0.785	.040	7	view →
PDAC	DFS	Tertile	III,IV	1.000	0.507	.013	6	view →
LUAD	DFS	Median	All	0.891	1.000	.014	4	view →
LSCC	DFS	Quartile	II,III,IV	0.888	0.200	.024	3	view →
GBM	OS	Quartile	All	0.501	0.713	.025	2	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LRRC20–CCRCC (OS)

Open the CCRCC breakdown →